Join us as we unveil the content that made the greatest impact in 2024. From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Immuno-oncology is at the heart of Dr Hassan Abushukair’s inspiring journey from Jordan to the USA. A rising star in the field, Hassan combines clinical expertise and bioinformatics to unravel the immune system’s role in cancer, advancing precision medicine. With over 20 publications and prestigious awards, he is paving the way for innovative therapies while championing mentorship and patient-centred research.
Each year, the United European Gastroenterology (UEG) organisation awards a prestigious €50,000 Research Prize to recognise excellence in basic science, translational, or clinical research. This award supports future innovative scientific projects from inception to completion, emphasizing their transformative potential to enhance patient care. This year’s recipient, Dr. Enrique de-Madaria, Gastroenterologist and Coordinator of the Biliary-Pancreatic Unit at Dr. Balmis Hospital in Alicante, Spain, has been honoured for his groundbreaking work in fluid resuscitation for acute pancreatitis. Over the past decade, his multicentre studies—bolstered by national and international collaborations—have redefined clinical practice and established new standards of care.
IgG4-RD is a rare, chronic, relapsing condition characterized by fibroinflammatory lesions rich in CD19+ B cells, which can damage multiple organ systems and lead to organ failure.1 With no approved therapies, glucocorticoids are the primary treatment, but their long-term use is associated with adverse effects and inadequate disease control.1
Research presented at the ACG 2024 Annual Scientific Meeting found no increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) treated with Janus kinase inhibitors (JAKi) compared to those receiving anti-tumor necrosis factor (anti-TNF) therapy. This retrospective cohort study, led by Dr. Saqr Alsakarneh, analyzed data from 7,480 adult patients, showing comparable MACE and VTE rates across both treatment groups, even in older adults. These findings provide reassurance regarding the cardiovascular safety of JAKi in managing IBD, although further prospective studies are needed to validate long-term outcomes.
New research presented at UEG Week 2024 has introduced a strategy that could considerably reduce the need for insulin therapy in patients with type 2 diabetes (T2D).¹ The study investigated a novel approach combining ReCET (Re-Cellularization via Electroporation Therapy) with the ...
Watch leading experts discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.
Watch Drs Ronald Vender, Richard Warren and Xenofon Baraliakos discuss UCB’s contributions to the treatment of immunological disease.
On September 23, 2024, the U.S. Food and Drug Administration (FDA) approved bimekizumab-bkzx (BIMZELX®, UCB) for the treatment of active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).1 This makes bimekizumab-bkzx ...
Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the oesophagus that is progressive in nature and increasingly prevalent worldwide.1Â The condition is driven by antigen-induced type 2 inflammation, leading to the infiltration of eosinophils, which causes esophageal dysfunction and ...
A new study published in RMD Open has revealed that individuals with rheumatoid arthritis (RA) are significantly more likely to experience cognitive impairment. The study, which involved 70 RA patients and 70 matched healthy controls, showed that 60% of RA patients scored below the threshold for cognitive impairment on the Montreal Cognitive Assessment (MoCA), compared to 40% of the control group. This cognitive decline was most pronounced in visuospatial-executive function, memory and abstraction.
The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...
As we have come to expect, EULAR 2024 was a busy and productive meeting, packed with news and lively discussions among rheumatologists. The conference, which took place in Vienna, Austria, highlighted a wealth of innovative research and significant advancements in rheumatology. ...
Watch highlights of three ADVENT symposia presented at EADV 2023
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.